Jan A. Burger, MD, PhD

About Dr. Burger

Dr. Burger is a physician-scientist internationally recognized for his groundbreaking research and clinical leadership in the treatment of chronic lymphocytic leukemia (CLL). He currently serves as a Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.

Dr. Burger’s research is at the forefront of efforts to understand how malignant B lymphocytes interact with their surrounding tissue microenvironment—a critical factor in leukemia and lymphoma progression. His laboratory has made significant advances in identifying how the B cell receptor (BCR) signaling pathway, influenced by tumor-associated macrophages known as nurse-like cells, drives the survival and proliferation of CLL cells. His work has led to the development and optimization of targeted therapies that inhibit key kinases involved in BCR signaling, including Bruton’s tyrosine kinase (BTK), PI3K, and spleen tyrosine kinase (SYK).

A pioneer in translational research, Dr. Burger has played a leading role in clinical trials that revolutionized the treatment landscape of CLL. His contributions were instrumental in the clinical development of ibrutinib, the first-in-class BTK inhibitor, which has since become a standard-of-care therapy for patients with CLL. His current research focuses on next-generation kinase inhibitors and innovative treatment regimens that aim to maximize therapeutic efficacy while minimizing treatment duration and toxicity.

In addition to his scientific contributions, Dr. Burger is a frequent lecturer at international conferences and a respected mentor to trainees in oncology and hematology. His work bridges the gap between laboratory discoveries and clinical applications, embodying the principles of precision medicine.

Through his leadership in both basic science and clinical research, Dr. Burger continues to shape the future of targeted therapies in CLL and other B-cell malignancies.